Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTRIPHYLLINE vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of bronchial asthma,Chronic bronchitis,Pulmonary emphysema,Apnea of prematurity (off-label)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Hepatic via CYP1A2 and CYP2E1; exhibits nonlinear pharmacokinetics at high doses.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40-60% bound to plasma albumin; decreases in neonates and patients with hepatic disease
65% bound to albumin
0.45-0.7 L/kg; approximates total body water; increased in premature infants (0.8-1.0 L/kg) and in cirrhosis
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral: 100%; rectal: >90%
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
For GFR 30-50 m L/min: reduce dose by 50% and extend interval to every 8-12 hours. For GFR <30 m L/min: avoid use or reduce to 200 mg every 12 hours with close monitoring.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh A: no adjustment needed. Child-Pugh B: reduce dose by 50% and monitor levels. Child-Pugh C: contraindicated or use with extreme caution, maximum 200 mg every 12 hours.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
For children >1 year: 5 mg/kg orally every 6 hours; maximum 200 mg per dose. For infants 6-12 months: 4 mg/kg every 8 hours. Not recommended for neonates.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Initiate at 200 mg orally every 8-12 hours; titrate slowly, monitor for CNS excitation and arrhythmias. Use lower end of dosing range due to reduced clearance.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None.
No FDA black box warning.
Seizures: Risk increases with high serum levels (particularly >20 mcg/m L) and in patients with preexisting seizure disorders.,Cardiotoxicity: Includes ventricular arrhythmias and atrial fibrillation; risk increased with underlying cardiac disease or hypoxemia.,Gastrointestinal effects: Nausea, vomiting, and diarrhea are common; may indicate toxicity.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to oxitriphylline or any xanthine derivative,Acute myocardial infarction,Uncontrolled arrhythmias,Preexisting seizure disorder (relative)
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid or limit high-caffeine foods and beverages (coffee, tea, chocolate, cola) as they may potentiate side effects. Also avoid chargrilled meats and cruciferous vegetables (e.g., broccoli, cabbage) as they may alter theophylline metabolism.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Pregnancy Category C. No well-controlled studies in humans. Animal studies have shown adverse effects (fetal resorption, skeletal anomalies) at high doses. Risk cannot be ruled out; use only if clearly needed. First trimester: potential for teratogenicity based on animal data. Second/third trimesters: potential for respiratory alkalosis and electrolyte disturbances in fetus due to maternal alkalosis; avoid near term as may cause fetal tachycardia.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Excreted into breast milk in small amounts. M/P ratio not determined. Use with caution; monitor infant for irritability, insomnia, and jitteriness. American Academy of Pediatrics considers compatible with breastfeeding, but preferable to use lowest effective dose.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Pregnancy decreases theophylline clearance by approximately 20-30% due to reduced hepatic metabolism and increased volume of distribution. Dose reduction may be required to achieve therapeutic levels; monitor serum levels frequently. Avoid loading doses in early labor due to prolonged half-life.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Oxtriphylline is a bronchodilator (xanthine derivative) with similar efficacy to theophylline. Monitor serum theophylline levels (target 5-15 mcg/m L) due to narrow therapeutic index. Caution in hepatic impairment, heart failure, and elderly. Drug interactions include CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., carbamazepine, rifampin). Avoid rapid IV administration to prevent hypotension and arrhythmias.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not crush or chew enteric-coated tablets.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, or seizures.,Do not stop abruptly; taper under medical supervision.,Keep a diary of peak flow readings if used for asthma.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
"Oxtriphylline, a xanthine derivative, is a prodrug of theophylline and is primarily metabolized by hepatic cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, induces CYP3A4 and other metabolic enzymes, potentially increasing the clearance of oxtriphylline's active metabolite theophylline. This reduction in theophylline exposure may decrease its bronchodilator efficacy, leading to worsening of respiratory symptoms in patients with asthma or COPD."
"Oxtriphylline, a xanthine bronchodilator, is metabolized primarily by CYP1A2 and CYP3A4. Azithromycin, a macrolide antibiotic, can inhibit CYP3A4, leading to decreased clearance of oxtriphylline and increased plasma concentrations. This may result in dose-related toxicity, including nausea, vomiting, tachycardia, and seizures."
"Oxtriphylline, a xanthine derivative used as a bronchodilator, may inhibit the metabolism of abiraterone, a CYP3A4 substrate, leading to increased serum concentrations of abiraterone. This elevation can potentiate the risk of abiraterone-related adverse effects such as hepatotoxicity, hypertension, hypokalemia, and fluid retention. Additionally, Oxtriphylline's own clearance may be affected, increasing the likelihood of xanthine toxicity manifesting as nausea, vomiting, or cardiac arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTRIPHYLLINE vs AEROLATE, answered by our medical review team.
OXTRIPHYLLINE is a Bronchodilator that works by Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTRIPHYLLINE and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTRIPHYLLINE is: 200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTRIPHYLLINE and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTRIPHYLLINE is classified as Category C. Pregnancy Category C. No well-controlled studies in humans. Animal studies have shown adverse effects (fetal resorption, skeletal anomalies) at high doses. Risk cannot be ruled out. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.